|
|
Volumn 22, Issue 7, 2004, Pages 787-
|
|
Celltech acquisition sends mixed messages
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CERTOLIZUMAB PEGOL;
CETIRIZINE;
ACHIEVEMENT;
BIOTECHNOLOGY;
CLINICAL TRIAL;
CROHN DISEASE;
DRUG INDUSTRY;
DRUG MARKETING;
ECONOMIC ASPECT;
FINANCIAL MANAGEMENT;
HUMAN;
NOTE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
UNITED KINGDOM;
UNITED STATES;
BELGIUM;
BIOTECHNOLOGY;
DRUG INDUSTRY;
GREAT BRITAIN;
POLYETHYLENE GLYCOLS;
|
|
EID: 3042703071
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0704-787 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|